Published in Pharma Investments, Ventures and Law Weekly, September 19th, 2004
Net loss, under generally accepted accounting principles (GAAP), was approximately $29.3 million, or $0.41 per share, compared to a GAAP net loss of $23.4 million, or $0.39 per share, for the second quarter 2003. Non-GAAP net loss, excluding restructuring expense, acquired in-process research and development, and noncash charges for stock compensation and amortization of intangibles, was approximately $27.0 million, or $0.37 per share, compared to approximately $23.9 million, or $0.40 per share, for the second quarter of 2003.
Cash, cash equivalents, short-term...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.